Comparison of RNA Marker Panels for Circulating Tumor Cells and Evaluation of Their Prognostic Relevance in Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Feb 25

PMID 36831613

Authors

Eva Welsch

Eva Schuster

Michael Krainer

Maximilian Marhold

Rupert Bartsch

Michael B Fischer

Michael Hermann

Gabriele Hastermann

Heidemarie Uher

Gerhard Sliutz

Birgit Anker

Robert Zeillinger

Eva Obermayr

Affiliations

Soon will be listed here.

Abstract

Liquid biopsy is a promising tool for therapy monitoring of cancer patients, but a need for further research in this field exists in order to improve sensitivity, specificity, standardization and minimize costs. In our present study, we evaluated two panels of transcripts related with the presence of circulating tumor cells (CTCs) (Panel 1: , , and Panel 2: , , , , and ) in two cohorts of breast cancer patients (metastatic and early). A blood cell fraction possibly containing CTCs was isolated with density gradient centrifugation, followed by RNA isolation and qPCR using TaqMan or RT-qPCR using hybridization probes. The positivity rates of the investigated panels were similar, albeit higher in metastatic (69.4% Panel 1, 75.0% Panel 2; total 86.1%) compared to early (18.9% Panel 1, 23.3% Panel 2; total 31.1%) breast cancer patients. , , , , , and individually correlated with shorter overall survival in the metastatic patient cohort. The findings highlight the additional value of Panel 2 markers, which are in contrast to and not solely linked to an epithelial phenotype.

Citing Articles

Circulating Tumor Cells: Origin, Role, Current Applications, and Future Perspectives for Personalized Medicine.

Rapanotti M, Cenci T, Scioli M, Cugini E, Anzillotti S, Savino L Biomedicines. 2024; 12(9).

PMID: 39335650 PMC: 11429165. DOI: 10.3390/biomedicines12092137.

PPIC-labeled CAFs: Key players in neoadjuvant chemotherapy resistance for gastric cancer.

Yin H, Sun L, Yuan Y, Zhu Y Transl Oncol. 2024; 48:102080.

PMID: 39116799 PMC: 11362775. DOI: 10.1016/j.tranon.2024.102080.

Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting.

Strati A, Markou A, Kyriakopoulou E, Lianidou E Cancers (Basel). 2023; 15(7).

PMID: 37046848 PMC: 10092977. DOI: 10.3390/cancers15072185.

References

Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A . Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol. 2006; 24(23):3756-62. DOI: 10.1200/JCO.2005.04.5948. View

Muller V, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E . Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 2012; 14(4):R118. PMC: 3680931. DOI: 10.1186/bcr3243. View

Bidard F, Michiels S, Riethdorf S, Mueller V, Esserman L, Lucci A . Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst. 2018; 110(6):560-567. DOI: 10.1093/jnci/djy018. View

Cohen E, Jayachandran G, Moore R, Cristofanilli M, Lang J, Khoury J . A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix PC1 System. Cancers (Basel). 2022; 14(21). PMC: 9656921. DOI: 10.3390/cancers14215238. View

Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E . Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer. 2009; 101(4):589-97. PMC: 2736820. DOI: 10.1038/sj.bjc.6605183. View

Ring A, Spataro M, Wicki A, Aceto N . Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer. Front Cell Dev Biol. 2022; 10:929893. PMC: 9274007. DOI: 10.3389/fcell.2022.929893. View

Miller M, Robinson P, Wagner C, OShannessy D . The Parsortix™ Cell Separation System-A versatile liquid biopsy platform. Cytometry A. 2018; 93(12):1234-1239. PMC: 6586069. DOI: 10.1002/cyto.a.23571. View

Harbeck N, Gnant M . Breast cancer. Lancet. 2016; 389(10074):1134-1150. DOI: 10.1016/S0140-6736(16)31891-8. View

Sajdik C, Schuster E, Holzer B, Krainer M, Deutschmann C, Peter S . Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients. Breast Cancer Res Treat. 2022; 196(1):75-85. PMC: 9550727. DOI: 10.1007/s10549-022-06717-x. View

10.

Obermayr E, Cacsire Castillo-Tong D, Pils D, Speiser P, Braicu I, Van Gorp T . Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. Gynecol Oncol. 2012; 128(1):15-21. DOI: 10.1016/j.ygyno.2012.09.021. View

11.

Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B . Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920-8. DOI: 10.1158/1078-0432.CCR-06-1695. View

12.

Obermayr E, Sanchez-Cabo F, Tea M, Singer C, Krainer M, Fischer M . Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer. 2010; 10:666. PMC: 3013085. DOI: 10.1186/1471-2407-10-666. View

13.

Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D, Malamos N . A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int J Cancer. 2006; 119(7):1654-9. DOI: 10.1002/ijc.22017. View

14.

Bidard F, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P . Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 2009; 21(4):729-733. DOI: 10.1093/annonc/mdp391. View

15.

Hartkopf A, Banys M, Krawczyk N, Wallwiener M, Schneck H, Neubauer H . Circulating Tumor Cells in Early-Stage Breast Cancer. Geburtshilfe Frauenheilkd. 2017; 71(12):1067-1072. PMC: 5396553. DOI: 10.1055/s-0031-1280463. View

16.

Ferlay J, Colombet M, Soerjomataram I, Parkin D, Pineros M, Znaor A . Cancer statistics for the year 2020: An overview. Int J Cancer. 2021; . DOI: 10.1002/ijc.33588. View

17.

Konigsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F . Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 2011; 50(5):700-10. DOI: 10.3109/0284186X.2010.549151. View

18.

Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S . Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol. 2002; 20(16):3404-12. DOI: 10.1200/JCO.2002.08.135. View

19.

Sparano J, ONeill A, Alpaugh K, Wolff A, Northfelt D, Dang C . Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018; 4(12):1700-1706. PMC: 6385891. DOI: 10.1001/jamaoncol.2018.2574. View

20.

Pedersen R, Esen B, Mellemkjaer L, Christiansen P, Ejlertsen B, Lash T . The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis. J Natl Cancer Inst. 2021; 114(3):391-399. PMC: 8902439. DOI: 10.1093/jnci/djab202. View